Leap Therapeutics Inc
LPTX2.050USD
0.0000.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
84.95M시가총액
손실P/E TTM
자세한 내용은 Leap Therapeutics Inc 회사
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc 정보
종목 코드 LPTX
회사 이름Cypherpunk Technologies Inc
상장일Jan 24, 2017
CEOOnsi (Douglas E)
직원 수52
유형Ordinary Share
회계 연도 종료Jan 24
주소47 Thorndike Street
도시CAMBRIDGE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호02142
전화16172524343
웹사이트https://www.leaptx.com/
종목 코드 LPTX
상장일Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
--
--
Mr. Mark O'Mahony
Mr. Mark O'Mahony
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Jan 5
마지막 업데이트: Mon, Jan 5
주주
주주 유형
주주
주주
비율
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
기타
59.09%
주주
주주
비율
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
기타
59.09%
주주 유형
주주
비율
Family Office
14.62%
Corporation
11.53%
Individual Investor
11.07%
Investment Advisor
6.53%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
기타
48.65%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
109
9.04M
15.96%
-11.00M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Winklevoss Capital Management, LLC
8.28M
14.62%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
10.59%
+6.00M
--
Nov 12, 2025
Gilead Sciences Inc
5.32M
9.39%
--
--
Oct 24, 2025
The Vanguard Group, Inc.
1.16M
2.05%
--
--
Sep 30, 2025
BofA Global Research (US)
1.44M
2.55%
+1.44M
+451295.63%
Sep 30, 2025
Acadian Asset Management LLC
1.24M
2.18%
--
--
Sep 30, 2025
Beigene Ltd
1.22M
2.15%
+1.22M
--
Oct 31, 2024
Simplify Asset Management Inc
975.61K
1.72%
+118.25K
+13.79%
Sep 30, 2025
HealthCare Ventures LLC
676.32K
1.19%
-20.91K
-3.00%
Oct 24, 2025
Geode Capital Management, L.L.C.
312.19K
0.55%
--
--
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
비율0.37%
iShares Micro-Cap ETF
비율0%
Dimensional US Core Equity 1 ETF
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
날짜
배당락일
유형
비율
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
